Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
Browse
Conferences
Browse
< Back to conference highlights < Previous conference
Subscribe
Bookmark and Share

ESMO 2016

7th - 11th Oct 2016

Videos

News

Conference Reports

26.10.16

What does the Association of European Cancer Leagues (ECL)...

26.10.16

no rating
Coming of age for CDK 4/6 inhibitors: Welcome and...

26.10.16

no rating
What are CDKs?

26.10.16

no rating
CDK clinical trial results, benefit, side effects and costs

26.10.16

no rating
Extending indication of CDK 4/6 inhibitors in the adjuvant...

26.10.16

no rating
Current indications for CDK 4/6 inhibitors (plus...

26.10.16

no rating
Coming of age for CDK 4/6 inhibitors: Interactive session...

26.10.16

Biomarkers of sensitivity and resistance

24.10.16

Editor's ESMO 2016 roundup

24.10.16

Abiraterone in patients with recurrent epithelial ovarian...

21.10.16

Fatigue in men with castration resistant prostate cancer...

20.10.16

no rating
PDL-1 assay concordance

17.10.16

CDK4/6 inhibition: PALOMA2 versus MONALEESA2

17.10.16

First evidence of significant clinical activity of PD1...

14.10.16

CDK4/6 inhibitors for metastatic breast cancer

12.10.16

TRAIL induced apoptosis for cancer stem cells

12.10.16

Carcinoid syndrome

12.10.16

Who should receive combination therapy for ER positive...

12.10.16

Positive lessons of negative trials

12.10.16

Drug repurposing of propranolol

12.10.16

ESMO 2016 conference highlights

12.10.16

Risk of serious and fatal adverse events with sorafenib use...

12.10.16

Combination of MEDI0680, an anti-PD-1 antibody, with...

12.10.16

LUME study of nintedanib finds improved PFS, but no overall...

10.10.16

ESMO 2016 prostate cancer highlights

10.10.16

no rating
Left versus right sided GI tumour response in the CRYSTAL...

10.10.16

Looking for new pathways in colorectal cancer

10.10.16

no rating
Caring for lung cancer patients

10.10.16

Oncolytic virotherapy using coxsackie virus

10.10.16

Results of the Activ8 trial of novel immunotherapy motolimod

10.10.16

Lurbinectedin in PARP resistant breast cancer

10.10.16

Monitoring patterns of care in mCRPC patients with the help...

10.10.16

Lurbinectedin in BRCA 1/2 breast cancer

10.10.16

Olaparib and paclitaxel for 2nd line gastric cancer therapy

10.10.16

Innovative uses of kinase inhibitors in cancer

10.10.16

no rating
Comment: Ipilimumab in high risk stage III melanoma

10.10.16

Comment: Niraparib for ovarian cancer

10.10.16

Comment: Ribociclib for breast cancer

10.10.16

Treating CNS metastases from breast cancer with a...

10.10.16

Highlights of ESMO 2016

10.10.16

Adjuvant sunitinib for renal cell carcinoma

10.10.16

no rating
Longer disease-free survival in phase III trial of sunitinib...

10.10.16

no rating
Custirsen shows no survival benefit in metastatic prostate...

10.10.16

Benefits of adjuvant chemo for soft tissue sarcoma patients

10.10.16

Significant survival gains for neoadjuvant chemotherapy for...

10.10.16

no rating
Cabozantinib over sunitinib for metastatic renal cell...

10.10.16

Promising results in metastatic bladder cancer using...

10.10.16

Negative trial results of custirsen for metastatic prostate...

10.10.16

Cabozantinib improves PFS in metastatic renal cell carcinoma

09.10.16

ESMO 2016: Expert discussion on prostate cancer: Treatment...

09.10.16

Advances for NSCLC in review

09.10.16

no rating
Ceritinib following crizotinib relapse for ALK positive...

09.10.16

Atezolizumab v docetaxel for NSCLC: results from the OAK...

09.10.16

Significant survival gains with atezolizumab for NSCLC

09.10.16

Pembrolizumab new option for firstline treatment of advanced...

09.10.16

Pembrolizumab plus chemo as firstline therapy for NSCLC

09.10.16

ASCEND-5: Ceritinib for ALK positive NSCLC previously...

09.10.16

Pembrolizumab 'should be first line treatment' for high PD1...

09.10.16

Firstline pembrolizumab plus chemo improves NSCLC outcomes

09.10.16

KRAS in the clinic and conference

09.10.16

no rating
A potential prognostic biomarker of chemoresistance in mCRC...

09.10.16

no rating
Thousands of melanoma patients in Europe have no access to...

09.10.16

no rating
Phase I results of a novel FGFR inhibitor

09.10.16

Firstline pembrolizumab for metastatic urothelial cancer

08.10.16

no rating
Adjuvant immunotherapy improves melanoma outcomes

08.10.16

Adjuvant cetuximab in the PETACC8 trial for stage III colon...

08.10.16

FALCON trial: fulvestrant vs. anastrozole for HR advanced...

08.10.16

Fulvestrant in FALCON trial improves PFS in advanced breast...

08.10.16

Dabrafenib shows higher response and lower toxicity in...

08.10.16

no rating
Ribociclib improves progression-free survival in advanced...

08.10.16

Outcome of ovarian cancer patients was significantly...

08.10.16

Niraparib significantly improves outcomes for ovarian cancer...

08.10.16

Ipilimumab as adjuvant therapy improves OS in high risk...

08.10.16

Ribociclib improves PFS for postmenopausal women with...

Conferences Calendar

Information on upcoming conferences > find out where ecancer is filming next sign up for coverage submit your event

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation